All In Biotech

BLA 761071 · Sandoz INC

Hyrimoz

Adalimumab-Adaz · Injection · Tumor Necrosis Factor Blocker

Last checked: Nov 20, 2026Latest source record: Oct 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Oct 30, 2018

Approved uses

4

Original approval plus efficacy supplements

Registered trials

523

198 Phase 3, 51 recruiting

FAERS reports

55,076

50,853 serious, 8,503 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products, including Adalimumab-adaz, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue Adalimumab-adaz if a patient develops a serious infection or sepsis. Reported infections include: • Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before Adalimumab-adaz use and during therapy. Initiate treatment for latent TB prior to Adalimumab-adaz use. • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis,...

What it is approved for

From the label in effect Oct 21, 2025.

Adalimumab-adaz is a tumor necrosis factor (TNF)-blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. (1.1) • Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. (1.2) • Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. (1.3) • Reducing signs and symptoms in adult patients with active ankylosing spondylitis. (1.4) • Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. (1.5) • Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) • Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) • Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis Adalimumab-adaz is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis....

Mechanism: Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement. Adalimumab products do not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, and AS and play an important role in both the pathologic inflammation and the joint destruction that are...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • HYRIMOZ · ADALIMUMAB-ADAZ 40MG/0.8ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Adalimumab" as an intervention, any sponsor and status, largest first.

All 523 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective11,624
  • off label use9,662
  • rheumatoid arthritis6,561
  • pain6,472
  • fatigue6,470
  • arthralgia6,308
  • rash5,346
  • condition aggravated5,087
  • diarrhoea4,907
  • drug intolerance4,718
  • nausea4,651
  • joint swelling4,643

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
200525
200610
200744
2008136
2009138
2010257
2011208
2012256
2013295
2014277
2015318
2016505
2017727
20181,255
20192,236
20203,159
20213,641
20225,374
20238,070
202410,487
202510,501
20267,149

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Jan 13, 2026

    Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-68). Equivalent Sandoz format is available.

  • To Be Discontinued · updated Jan 13, 2026

    Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-36). Equivalent Sandoz format is available.

  • To Be Discontinued · updated Jan 13, 2026

    Hyrimoz, Injection, Kit (NDC 61314-531-64). Equivalent Sandoz format is available.

  • To Be Discontinued · updated Jan 13, 2026

    Hyrimoz, Injection, Kit (NDC 61314-517-36). Equivalent Sandoz format is available.

  • To Be Discontinued · updated Jan 13, 2026

    Hyrimoz, Injection, 40 mg/.4 mL (NDC 61314-473-64). Equivalent Sandoz format is available.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,624 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.